| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | K. H. Lee | |
| H. K. Wang | |||
| S. L. Morris-Natschke | |||
| P2860 | cites work | Cancer Research | Q326097 |
| Molecular Pharmacology | Q1943386 | ||
| Revue des Maladies Respiratoires | Q15708750 | ||
| Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells | Q28307355 | ||
| Phase I-II study on weekly administration of pirarubicin in patients with metastatic breast cancer | Q28334058 | ||
| Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation | Q28342992 | ||
| Inhibition of DNA Topoisomerases by Sanguiin H-6, a Cytotoxic Dimeric Ellagitannin fromSanguisorba officinalis1 | Q29394453 | ||
| Phase II study of amonafide in advanced breast cancer | Q67886427 | ||
| Phase II study of amonafide in advanced and recurrent sarcoma patients | Q68012219 | ||
| Phase II trial of pirarubicin in epidermoid carcinoma of the head and neck | Q68132938 | ||
| Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion | Q68202658 | ||
| 1-Amino-substituted 4-methyl-5H-pyrido[4,3-b]indoles (gamma-carbolines) as tricyclic analogues of ellipticines: a new class of antineoplastic agents | Q68259796 | ||
| Antitumor agents. 113. New 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II | Q68474681 | ||
| Saintopin, a new antitumor antibiotic with topoisomerase II dependent DNA cleavage activity, from Paecilomyces | Q68489520 | ||
| Improved antitumor effects of 3'-deamino-3'-morpholino derivatives of pirarubicin | Q68651172 | ||
| Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin's lymphoma in the elderly | Q68685457 | ||
| Synthesis and antitumor activity of 1-[[(dialkylamino)alkyl]amino]-4-methyl-5H-pyrido[4,3-b]benzo[e]- and -benzo[g])indoles. A new class of antineoplastic agents | Q68761476 | ||
| DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts | Q69360455 | ||
| Elsamicins, new antitumor antibiotics related to chartreusin. I. Production, isolation, characterization and antitumor activity | Q69570643 | ||
| Isolation of lapachol from Diphysa robinoides | Q69622218 | ||
| Antimycotic effects of the novel antitumor agents fostriecin (CI-920), PD 113,270 and PD 113,271 | Q69663637 | ||
| N-salicylidene derivatives of pirarubicin | Q69666437 | ||
| The structure of a new antibiotic, terpentecin | Q69806901 | ||
| Inhibition of type II topoisomerase by fostriecin | Q69842894 | ||
| Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I | Q70106083 | ||
| Antitumor agents. 3. Synthesis and biological activity of 4 beta-alkyl derivatives containing hydroxy, amino, and amido groups of 4'-O-demethyl-4-desoxypodophyllotoxin as antitumor agents | Q70459534 | ||
| A structure-activity relationship study of batracylin analogues | Q70463441 | ||
| Tannins as potent inhibitors of DNA topoisomerase II in vitro | Q70472336 | ||
| Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives | Q70507714 | ||
| 2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent | Q70626217 | ||
| Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I | Q70915257 | ||
| 6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships | Q71121688 | ||
| Bisindolylmaleimides linked to DNA minor groove binding lexitropsins: synthesis, inhibitory activity against topoisomerase I, and biological evaluation | Q71176187 | ||
| Antitumor agents. 164. Podophenazine, 2'',3''-dichloropodophenazine, benzopodophenazine, and their 4 beta-p-nitroaniline derivatives as novel DNA topoisomerase II inhibitors | Q71218535 | ||
| Inhibition of topoisomerase I function by nitidine and fagaronine | Q30466358 | ||
| Inhibition of DNA topoisomerase II by azaelliptitoxins functionalized in the variable substituent domain | Q30468553 | ||
| Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles | Q33355908 | ||
| Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study | Q33359851 | ||
| Phase II clinical study of pirarubicin in hormone resistant prostate cancer | Q33359865 | ||
| Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma | Q33360943 | ||
| Evaluation of amonafide in cervical cancer, phase II. A SWOG study | Q33363415 | ||
| Phase II study of amonafide in advanced pancreatic adenocarcinoma | Q33377617 | ||
| Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study | Q33377619 | ||
| Phase II Trial of Amonafide in Patients with Stage III and IV Non-Small-Cell Lung Cancer | Q33379793 | ||
| Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study. | Q33491277 | ||
| A Gynecologic Oncology Group phase II study of amonafide (NSC #308847) in squamous cell carcinoma of the cervix. | Q33492450 | ||
| Phase II trial of amonafide in advanced pancreas cancer. A Southwest Oncology Group study | Q33493283 | ||
| Evaluation of amonafide in disseminated malignant melanoma. A Southwest Oncology Group study | Q33493285 | ||
| Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study. | Q33493548 | ||
| Amonafide treatment of refractory esophageal cancer. A Southwest Oncology Group study | Q33493780 | ||
| Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC). | Q33494104 | ||
| Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study. | Q33494563 | ||
| Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration | Q33495553 | ||
| Antitumor agents, 129. Tannins and related compounds as selective cytotoxic agents | Q34260496 | ||
| Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. | Q34356700 | ||
| A theoretical evaluation of the effect of netropsin binding on the reactivity of DNA towards alkylating agents | Q35695571 | ||
| DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. | Q36512149 | ||
| Ravidomycin (AY-25,545), a new antitumor antibiotic. | Q36633679 | ||
| Gilvocarcins, new antitumor antibiotics. 1. Taxonomy, fermentation, isolation and biological activities | Q36658813 | ||
| Synthesis, topoisomerase I inhibitory activity, and in vivo evaluation of 11-azacamptothecin analogs | Q36699070 | ||
| Simultaneous determination of NK611, a novel water-soluble derivative of etoposide, and its metabolite (DeNK611) in dog plasma by column-switching high performance liquid chromatography | Q36781884 | ||
| Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin | Q36792791 | ||
| Topoisomerases, new targets in cancer chemotherapy | Q37877829 | ||
| DNA topoisomerases as targets for chemotherapy | Q39211064 | ||
| Inhibitors of DNA topoisomerases | Q39222432 | ||
| DNA topoisomerases--enzymes that catalyse the breaking and rejoining of DNA. | Q40139799 | ||
| Anthracycline antibiotics in cancer therapy. Focus on drug resistance | Q40388183 | ||
| Topoisomerase inhibitors. A review of their therapeutic potential in cancer | Q40499871 | ||
| DNA topoisomerases: essential enzymes and lethal targets | Q40678987 | ||
| Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes | Q40694350 | ||
| Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer | Q40751950 | ||
| The current status of camptothecin analogues as antitumor agents | Q40851253 | ||
| Antitumor agents. 163. Three-dimensional quantitative structure-activity relationship study of 4'-O-demethylepipodophyllotoxin analogs using the modified CoMFA/q2-GRS approach | Q40946047 | ||
| Status of new anthrapyrazole and pyrazoloacridine derivatives | Q41014822 | ||
| From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives | Q71227570 | ||
| Fermentation, isolation and characterization of antibiotic PR-1350 | Q71234600 | ||
| Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II | Q71657481 | ||
| Phase II study of amonafide in patients with recurrent glioma | Q71923695 | ||
| High-performance liquid chromatographic assay for the determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma | Q71996539 | ||
| Phase II evaluation of amonafide in advanced sarcoma: a Southwest Oncology Group study | Q72064922 | ||
| Phase II trial of pirarubicin in the treatment of advanced pancreatic cancer | Q72064925 | ||
| Acylshikonin analogues: synthesis and inhibition of DNA topoisomerase-I | Q72117381 | ||
| Rigid analogs of camptothecin as DNA topoisomerase I inhibitors | Q72117404 | ||
| Clinical and pharmacokinetic overview of parenteral etoposide phosphate | Q72149468 | ||
| Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group | Q72160196 | ||
| Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study | Q72160214 | ||
| Synthesis and biological evaluation of tetrademethyl isocolchicine derivatives as inhibitors of DNA topoisomerase action in vitro | Q72178073 | ||
| Streptonigrin-induced topoisomerase II sites exhibit base preferences in the middle of the enzyme stagger | Q72207073 | ||
| Azatoxin derivatives with potent and selective action on topoisomerase II | Q72269609 | ||
| Phase II study of elsamitrucin in non-small cell lung cancer | Q72298081 | ||
| Synthesis of novel water-soluble 7-(aminoacylhydrazono)-formyl camptothecins with potent inhibition of DNA topoisomerase I | Q72330013 | ||
| Antiproliferative actions of 7-substituted 1,3-dihydroxyacridones; possible involvement of DNA topoisomerase II and protein kinase C as biochemical targets | Q72330017 | ||
| A new topoisomerase II inhibitor, BE-22179, produced by a streptomycete. I. Producing strain, fermentation, isolation and biological activity | Q72346975 | ||
| Phase I clinical and pharmacokinetic study of oral etoposide phosphate | Q72354138 | ||
| Advanced colorectal adenocarcinoma: treatment with amonafide | Q72472464 | ||
| Amonafide as first-line chemotherapy for metastatic breast cancer | Q72520166 | ||
| Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I | Q72538750 | ||
| Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study | Q72616378 | ||
| Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial | Q72645082 | ||
| Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin | Q72650046 | ||
| Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues | Q72731983 | ||
| Synthesis and pharmacological evaluation of isoindolo[1,2-b]quinazolinone and isoindolo[2,1-a]benzimidazole derivatives related to the antitumor agent batracylin | Q72732106 | ||
| Phase II trial of menogaril in metastatic adenocarcinoma of the prostate. A Southwest Oncology Group study | Q72805225 | ||
| Menogaril: a new anthracycline agent entering clinical trials | Q72832999 | ||
| Anti-Cancer Drug Design | Q93797696 | ||
| Terpentecin and UCT4B, New Family of Topoisomerase II Targeting Antitumor Antibiotics Produced by Streptomyces: Producing Organism, Frementation and Large Scale Purification. | Q104403392 | ||
| Alkaloids of Ochrosia elliptica Labill.1 | Q104937747 | ||
| Inhibitors of DNA topoisomerase I isolated from the roots of Zanthoxylum nitidum | Q105142260 | ||
| Elenic acid, an inhibitor of Topoisomerase II, from a sponge, Plakinastrella sp. | Q105143194 | ||
| The constitution of clerocidin a new antibiotic isolated from | Q105153083 | ||
| Novel lignan derivatives as selective inhibitors of DNA topoisomerase II | Q105288181 | ||
| Induction of reversible protein-linked DNA breaks in human osteogenic sarcoma cells by novel cytocidal colchicine derivatives which inhibit DNA topoisomerase II in vitro: Absence of cross-resistance in a colchicine-resistant sub-clone | Q127235998 | ||
| Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy | Q41033289 | ||
| A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group | Q41080827 | ||
| Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer | Q41197213 | ||
| Stimulation by gamma-carboline derivatives (simplified analogues of antitumor ellipticines) of site specific DNA cleavage by calf DNA topoisomerase II. | Q41199103 | ||
| Antitumor agents. 166. Synthesis and biological evaluation of 5,6,7,8-substituted-2-phenylthiochromen-4-ones | Q41199150 | ||
| Substituted 2,5'-Bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity | Q41227295 | ||
| A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). | Q41293373 | ||
| Synthesis and Evaluation of Terbenzimidazoles as Topoisomerase I Inhibitors | Q41301752 | ||
| Antitumor agents--CLI. Bis(helenalinyl)glutarate and bis(isoalantodiol-B)glutarate, potent inhibitors of human DNA topoisomerase II. | Q41492026 | ||
| Antitumor agents. 144. New gamma-lactone ring-modified arylamino etoposide analogs as inhibitors of human DNA topoisomerase II. | Q41493640 | ||
| Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives | Q41509363 | ||
| The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. | Q41520249 | ||
| Biochemical characterisation of elsamicin and other coumarin-related antitumour agents as potent inhibitors of human topoisomerase II. | Q41584623 | ||
| Menogaril in the treatment of malignant mesothelioma: a phase II study | Q41616374 | ||
| Changes in nuclear chromatin related to apoptosis or necrosis induced by the DNA topoisomerase II inhibitor fostriecin in MOLT-4 and HL-60 cells are revealed by altered DNA sensitivity to denaturation | Q41617869 | ||
| Netropsin and bis-netropsin analogs as inhibitors of the catalytic activity of mammalian DNA topoisomerase II and topoisomerase cleavable complexes | Q41668908 | ||
| A new antitumor substance, BE-13793C, produced by a streptomycete. Taxonomy, fermentation, isolation, structure determination and biological activity | Q41678136 | ||
| Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle | Q41930981 | ||
| Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol | Q41989997 | ||
| Synthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-1,8 naphthalic acid | Q42242686 | ||
| The chemistry of the antibiotics chrysomycin A and B. Antitumor activity of chrysomycin A. | Q42265491 | ||
| Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship | Q42278420 | ||
| Doxorubicin inhibits human DNA topoisomerase I | Q43460458 | ||
| Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus | Q43499508 | ||
| Antitumor agents. 111. New 4-hydroxylated and 4-halogenated anilino derivatives of 4'-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II. | Q44981302 | ||
| Activity of batracylin (NSC-320846) against solid tumors of mice | Q45132890 | ||
| A new indolopyrrolocarbazole antitumor substance, ED-110, a derivative of BE-13793C | Q45797814 | ||
| Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum | Q48016179 | ||
| Using cell-fractionation and photochemical crosslinking methods to determine the cellular binding site(s) of the antitumor drug DMP 840. | Q49213221 | ||
| Novel antitumor agents CI-920, PD 113,270 and PD 113,271. I. Taxonomy, fermentation and biological properties. | Q50714146 | ||
| A novel antitumor compound, NC-190, induces topoisomerase II-dependent DNA cleavage and DNA fragmentation. | Q50755005 | ||
| Effects of two distamycin-ellipticine hybrid molecules on topoisomerase I and II mediated DNA cleavage: relation to cytotoxicity. | Q54167460 | ||
| Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units. | Q54193097 | ||
| Phase I study of retelliptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule. | Q54202849 | ||
| Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro. | Q54216962 | ||
| Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer. | Q54218013 | ||
| Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice. | Q54227751 | ||
| ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice. | Q54241910 | ||
| A benzophenazine derivative, N-beta-dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxy-benzo[a]phenazine-6-carboxamide, as a new antitumor agent against multidrug-resistant and sensitive tumors. | Q54335950 | ||
| Preclinical antitumor activity of batracylin (NSC 320846). | Q54377453 | ||
| Inhibition of topoisomerase II by a novel antitumor cyclic depsipeptide, BE-22179. | Q55012206 | ||
| Menogaril, an anthracycline derivative, inhibits DNA topoisomerase II by stabilizing cleavable complexes | Q55282720 | ||
| Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 | Q56864507 | ||
| Clerocidin, a terpenoid antibiotic, inhibits bacterial DNA gyrase | Q59695072 | ||
| Molecular Interactions of DNA-Topoisomerase I and II Inhibitor with DNA and Topoisomerases and in Ternary Complexes: Binding Modes and Biological Effects for Intoplicine Derivatives | Q62271248 | ||
| Synthesis and evaluation of new 6-amino- substituted benzo[c]phenanthridine derivatives | Q63369519 | ||
| DNA damage and topoisomerase II inhibition induced by a benzopsoralen derivative | Q64389648 | ||
| Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen | Q64389694 | ||
| Tetrahydropyranyl derivatives of daunomycin and adriamycin | Q66985557 | ||
| Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives | Q67507590 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 367-425 | |
| P577 | publication date | 1997-07-01 | |
| P1433 | published in | Medicinal Research Reviews | Q2436033 |
| P1476 | title | Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents | |
| P478 | volume | 17 |
| Q27318327 | A New Nanobody-Based Biosensor to Study Endogenous PARP1 In Vitro and in Live Human Cells |
| Q33902457 | A dumbbell double nicked duplex dodecamer DNA with a PEG6 tether. |
| Q38318734 | A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay |
| Q54120146 | A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP. |
| Q43653145 | A series of enediynes as novel inhibitors of topoisomerase I. |
| Q40409362 | Anticancer activity and possible mode of action of 4-O-podophyllotoxinyl 12-hydroxyl-octadec-Z-9-enoate |
| Q42000331 | Antiproliferative and Apoptosis Induction Potential of the Methanolic Leaf Extract of Holarrhena floribunda (G. Don). |
| Q57871346 | Bimodal, dimetallic lanthanide complexes that bind to DNA: the nature of binding and its influence on water relaxivity |
| Q28203339 | Camptothecins: a review of their chemotherapeutic potential |
| Q43213000 | DNA topoisomerase I inhibitors ameliorate seizure-like behaviors and paralysis in a Drosophila model of epilepsy |
| Q91666916 | Design and synthesis of DNA-intercalative naphthalimide-benzothiazole/cinnamide derivatives: cytotoxicity evaluation and topoisomerase-IIα inhibition |
| Q33951823 | Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents |
| Q43981278 | Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation |
| Q59550242 | Flavone and xanthone derivatives related to fluoroquinolones |
| Q36496588 | From bench to drug: human seizure modeling using Drosophila |
| Q59149996 | Imidazoles as potential anticancer agents |
| Q44564941 | Indolizino[1,2-b]quinolines derived from A-D rings of camptothecin: synthesis and DNA interaction |
| Q73939323 | Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells |
| Q38834102 | Investigation of the mechanism and apoptotic pathway induced by 4β cinnamido linked podophyllotoxins against human lung cancer cells A549. |
| Q30971685 | Linkage of a triple helix-forming oligonucleotide to amsacrine-4-carboxamide derivatives modulates the sequence-selectivity of topoisomerase II-mediated DNA cleavage |
| Q38335859 | Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage |
| Q38358485 | Mode of binding of the cytotoxic alkaloid berberine with the double helix oligonucleotide d(AAGAATTCTT)(2). |
| Q30854881 | Molecular cytogenetic analysis in mouse sperm of chemically induced aneuploidy: studies with topoisomerase II inhibitors. |
| Q40221376 | N, N' (4,5-dihydro-1h-imidazol-2-yl)3-aza-1,10-decane-diamine and N, N'(4,5-dihydro-1H-imidazol-2-yl)3-aza-1, 10-dodecane-diamine antagonize cell proliferation as selective ligands towards topoisomerase II. |
| Q34459467 | NPRL-Z-1, as a new topoisomerase II poison, induces cell apoptosis and ROS generation in human renal carcinoma cells |
| Q42063682 | Norfloxacin-induced DNA gyrase cleavage complexes block Escherichia coli replication forks, causing double-stranded breaks in vivo |
| Q34199783 | Research and future trends in the pharmaceutical development of medicinal herbs from Chinese medicine. |
| Q46535283 | Seizure suppression by top1 mutations in Drosophila. |
| Q39742187 | Selective inhibition of human leukemia cell growth and induction of cell cycle arrest and apoptosis by pseudolaric acid B. |
| Q72992497 | Stimulation of topoisomerase II-mediated DNA cleavage by an indazole analogue of lucanthone |
| Q74520769 | Structural insights into the function of type IB topoisomerases |
| Q27663556 | Structures of Minimal Catalytic Fragments of Topoisomerase V Reveals Conformational Changes Relevant for DNA Binding |
| Q74480895 | Substitution of 5-methylcytosines for cytosines enhances the stability of topoisomerase I-DNA complexes and modulates the sequence selectivity of camptothecin-induced DNA cleavage |
| Q40646513 | Synthesis and antiproliferative activity of basic thioanalogues of merbarone |
| Q78139204 | Synthesis and cytotoxicity of analogues of the antibiotic BE 10988 inhibitors of DNA topoisomerase II |
| Q73604371 | Synthesis, DNA binding, topoisomerases inhibition and cytotoxic properties of 4-arylcarboxamidopyrrolo-2-carboxyanilides |
| Q40482960 | Synthesis, spectroscopic, and biological studies of novel estolides derived from anticancer active 4-O-podophyllotoxinyl 12-hydroxyl-octadec-Z-9-enoate. |
| Q34075072 | The therapeutic potential of flavonoids |
| Q40902571 | Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4'-O-demethylepipodophyllotoxin conjugates |
| Q40703900 | Use of Chlamydomonas reinhardtii mutants for anticancer drug screening |
| Q33786691 | Vaccinia topoisomerase and Cre recombinase catalyze direct ligation of activated DNA substrates containing a 3'-para-nitrophenyl phosphate ester |
Search more.